Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Extended Sale! Save on premium data with Claim 60% OFF
Close

Nuformix PLC (NFXN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
0.2950 0.0000    0.00%
15:48:48 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 2,634,286
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.2608 - 0.2924
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BYW79Y38 
SEDOL:  BYW79Y3
Nuformix 0.2950 0.0000 0.00%

Nuformix PLC Company Profile

 
Read the Nuformix PLC company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

4

Equity Type

ORD

Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy-induced nausea and vomiting). NXP004 is a form of Olaparib, which is used for the treatment of several cancers.

Contact Information

Address 60 Gracechurch Street 6th Floor
London, EC3V 0HR
United Kingdom
Phone 44 1223 627222
Fax -
Web www.nuformix.com
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

NFXN Comments

Write your thoughts about Nuformix PLC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Hargreaves Smyth
Hargreaves Smyth Nov 10, 2022 9:03
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
low risk now, 3 mill mcap to 328mill yeah ill take that thanks when we get that order in within the next month or so. Take a look at the new presentation, its excellent, shows how much we are worth on first order, and we will get offers by the sound of it. Every faith in Dan, what a man!
Reply
0 0
Report
Criss Cross
Criss Cross Jul 12, 2022 8:25
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I think this is one of those shares that fell to its bottom, made progress and now has everyone's interest again. I think it is set to bounce to 1.0 fairly easy then onward and upwards depending on the company. Last raise was December and the presentation is on 22 September so Id expect good investment from there on in . RNS Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that both of the abstracts submitted for presentation at the European Respiratory Society ("ERS") International Congress 2022 in Barcelona on September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted for presentation. NXP002 is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: "We believe NXP002 offers tremendous potential as a novel inhaled treatment for IPF and potentially other fibrosing interstitial lung diseases ("ILDs"). The Company is progressing a pre-clinical programme to demonstrate how its proprietary new form of tranilast can down regulate fibrosis and inflammation following inhalation, whilst avoiding severe side effects, which are key issues in the treatment of IPF and other ILDs. We are therefore delighted that the abstracts describing our initial work have been accepted following peer review. Now, sounds better than good!!!
Reply
2 0
Report
Richard Stevens
Richard Stevens Aug 10, 2021 12:57
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
100% Bullish Here
Reply
3 2
Report
Richard Stevens
Richard Stevens Jan 29, 2020 18:18
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Strong buy...so much positive news. due q1
Reply
5 5
Report
Horun Meaj
Horun Meaj Jan 29, 2020 18:18
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What news? Never came...
Reply
2 1
Report
Dean Grande
Dean Grande Sep 06, 2019 9:21
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Nice to see a positive rns onwards and upwards
Reply
1 2
Report
Andrew Robertson
Andrew Robertson Jun 24, 2019 9:17
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
much more to come. Hold for next waves. sales news and other milestones such as NX0002
Reply
6 0
Report
Adrian Hampshire
Adrian Hampshire Apr 26, 2019 13:12
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This could seriously do multiples of current SP.
Reply
6 2
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email